AVITA Medical, Inc. (RCEL)
12.72
+0.71
(+5.91%)
USD |
NASDAQ |
Oct 02, 16:00
12.66
-0.06
(-0.51%)
After-Hours: 20:00
AVITA Medical Gross Profit Margin (Quarterly) : 81.87% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 81.87% |
| March 31, 2026 | 81.70% |
| December 31, 2025 | 81.24% |
| September 30, 2025 | 81.32% |
| June 30, 2025 | 81.17% |
| March 31, 2025 | 84.70% |
| December 31, 2024 | 87.61% |
| September 30, 2024 | 83.68% |
| June 30, 2024 | 86.11% |
| March 31, 2024 | 86.37% |
| December 31, 2023 | 87.35% |
| September 30, 2023 | 84.51% |
| Date | Value |
|---|---|
| June 30, 2023 | 81.25% |
| March 31, 2023 | 84.20% |
| December 31, 2022 | 85.75% |
| September 30, 2022 | 83.17% |
| June 30, 2022 | 83.37% |
| March 31, 2022 | 76.42% |
| June 30, 2021 | 80.08% |
| March 31, 2021 | 75.52% |
| December 31, 2020 | 83.91% |
| September 30, 2020 | 81.64% |
| June 30, 2020 | 77.46% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Halozyme Therapeutics, Inc. | 77.40% |
| Iovance Biotherapeutics, Inc. | 46.54% |
| Amgen, Inc. | 72.08% |
| Editas Medicine, Inc. | 96.50% |
| Arcus Biosciences, Inc. | 95.12% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -77.60% |
| Return on Invested Capital | -148.8% |
| Profit Margin (Quarterly) | -35.31% |
| Operating Margin (Quarterly) | -31.59% |
| Return on Net Operating Assets | -128.4% |